Interesting stock but too much risk given the $200M claim looming from ex CEO IMO.
- Forums
- ASX - By Stock
- NXL
- Ann: Nuix Revises FY21 Forecast Range
Ann: Nuix Revises FY21 Forecast Range, page-36
-
-
- There are more pages in this discussion • 184 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NXL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.38 |
Change
-0.120(3.43%) |
Mkt cap ! $1.096B |
Open | High | Low | Value | Volume |
$3.47 | $3.52 | $3.38 | $1.739M | 503.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
19 | 4265 | $3.37 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.39 | 4723 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 3767 | 3.370 |
12 | 5770 | 3.360 |
16 | 34038 | 3.350 |
5 | 4569 | 3.340 |
3 | 4300 | 3.330 |
Price($) | Vol. | No. |
---|---|---|
3.380 | 1433 | 9 |
3.390 | 4133 | 10 |
3.400 | 13208 | 9 |
3.410 | 11604 | 9 |
3.420 | 21407 | 9 |
Last trade - 13.58pm 15/07/2024 (20 minute delay) ? |
Featured News
NXL (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online